D2 What are the control arms for clinical trials in
recurrent ovarian cancer
•
For patents in which
platinum is still an option
3 control arms
identified depending on
–
Previous therapy
–
Number of prior lines
–
BRCA status
–
Geography /drug available and reimbursed
–
Drug contraindications
•
Options
–
Platinum combination
–
Platinum combination with licensed antioangiogenic therapy
–
Platinum combination followed by licensed PARPi
